Tokyo, August 8th, 2022 -- NTT Corporation (NTT) and Genesis Healthcare Co. (Genesis Healthcare) have entered a strategic business partnership, with NTT acquiring shares in Genesis Healthcare (1).
NTT, an established leader in IT infrastructure and services, is aiming to be the driving force behind Smart Healthcare in Japan. The partnership with Genesis Healthcare will accelerate the acquisition, analysis, utilization, and distribution of healthcare and medical data, including genetic data.
Committed to making a meaningful impact on people’s life, the partnership between NTT and Genesis Healthcare will leverage their respective knowledge and expertise in technology, genomic science, and data to build a healthy society based on respect, celebration of humanity and diversity, whereby everyone can access personally optimized precision healthcare.
Together, NTT and Genesis Healthcare will combine their respective expertise and collaborate in the following areas:
Promotion of joint research utilizing genetic data:
Genetic data is increasingly used in R&D to improve healthcare and medical care, including drug development and the elucidation of disease risks. Both companies will promote joint research and development based on genetic data, health checkups, lifelogs, and other data held by the companies, focusing on more than one million Japanese people. By providing statistical data to third-party research institutions, both companies will contribute to further advancement of healthcare and medical care to realize precision medicine and services.
Collaboration in genetic testing and analysis:
Using its expertise in genetic data analysis, Genesis Healthcare will work with NTT to realize a society where individuals can enjoy optimal care based on their data. Genesis Healthcare will provide genetic testing and other genomic related services, including health prevention, understanding of disease risks, health counseling, and lifestyle intervention.
Establishment of a joint-steering committee:
To keep pace with rapidly evolving technologies and social norms, a joint-steering committee will be established to drive synergies between the companies and create specific policies and measures to promote cooperation on ethical, legal, and social matters.
(1) NTT entered into a share purchase agreement with Genesis Healthcare's existing shareholder on August 8, 2022 to acquire 41,269 Genesis Healthcare shares (representing 19.3% of the total number of issued shares). NTT will nominate a non-executive director to the Board of Genesis Healthcare.
About NTT NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology, and managed services for cybersecurity, applications, workplace, cloud, data centers, and networks, all supported by our deep industry expertise and innovation. As a top 5 global technology and business solutions provider, our diverse teams operate in 80+ countries and regions and deliver services to over 190 of them. We serve over 80% of Fortune Global 100 companies and thousands of other clients and communities worldwide. For more information on NTT, visit www.global.ntt/. NTT and its partners are committed to contribute to a better society and progress through digitalization and DX. In the Healthcare and Medical sectors, our aim is to achieve Smart Healthcare, supporting the well-being of society through the promotion of DX in health and medical care as well as supporting the advancement of data-driven medical care solutions.
About Genesis Healthcare Co. Japan’s leading genetic testing and research company, Genesis Healthcare services medical institutions, corporations, and individuals since 2004 to benefit from personalized health and precision medicine. Through its patented AI driven prediction models, Genesis Healthcare provides advanced genetic testing services, from prevention to diagnostic. Most recently, Genesis Healthcare introduced Japan‘s first at-home whole genome sequencing test, covering more than 6,500 items. https://genesis-healthcare.jp/ https://www.genelife.jp/
Media Contact：
NTT Corporation
PR Office
Email: ntt-pr@ntt.com
Genesis Healthcare Co.
Public Relations Department
Email: press@genesis-healthcare.jp